Aralez Bio uses enzymes to make thousands of novel noncanonical amino acids (ncAAs) readily accessible for the first time at both lab and commercial scales via efficient, sustainable biomanufacturing. Our biocatalytic platform produces high-quality, chiral building blocks that enable drug developers to create the next generation of therapeutics to treat diseases previously considered undruggable. The diversity of ncAAs produced using enzymes are useful across all stages of drug discovery from screening to SAR. Additionally, the scalability of enzyme-based synthesis provides a reliable and economically viable path to clinical/commercial scale up. Noncanonical amino acids are found in blockbuster peptide drugs such as Semaglutide as well as in the latest generation of drug modalities such as macrocycles and antibody drug conjugates (ADCs). Aralez Bio makes unique, never-seen-before ncAAs and creates isomeric series of ncAAs that allow for fine-tuning of chemical properties.